Cargando…

A Dual Swine Challenge With Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae Used to Compare a Combination of Mixable Monovalent PCV2 and Monovalent M. hyopneumoniae Vaccines With a Ready-to Use PCV2 and M. hyopneumoniae Bivalent Vaccine

The present study evaluated the efficacy of swine vacciation using a combination of mixable monovalents for porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae against a ready-to-use bivalent vaccine under experimental conditions. Pigs at 21 days of age were administered either a combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Siyeon, Oh, Taehwan, Park, Kee Hwan, Cho, Hyejean, Chae, Chanhee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492382/
https://www.ncbi.nlm.nih.gov/pubmed/32984414
http://dx.doi.org/10.3389/fvets.2020.00579
_version_ 1783582368060145664
author Yang, Siyeon
Oh, Taehwan
Park, Kee Hwan
Cho, Hyejean
Chae, Chanhee
author_facet Yang, Siyeon
Oh, Taehwan
Park, Kee Hwan
Cho, Hyejean
Chae, Chanhee
author_sort Yang, Siyeon
collection PubMed
description The present study evaluated the efficacy of swine vacciation using a combination of mixable monovalents for porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae against a ready-to-use bivalent vaccine under experimental conditions. Pigs at 21 days of age were administered either a combination of two mixable monovalent vaccines or a bivalent vaccine containing PCV2 and M. hyopneumoniae. Vaccination was followed with an M. hyopneumoniae challenge at 42 days of age (−14 days post challenge, dpc) and a PCV2d challenge at 56 days of age (0 dpc). Each vaccinated and challenged group was compared with the unvaccinated and challenged group for clinical, microbiological, immunologic, and pathologic differences. Clinically, two vaccinated and challenged groups showed minimal respiratory diseases that was characterized by occasionally coughing and sneezing. A significant difference was not calculated in the average daily weight gain, nasal shedding of M. hyopneumoniae, and pathological lesions between two vaccinated and challenged groups. A combination of two monovalent vaccines mixed into a combo prior to vaccination followed by challenge resulted in increased numbers of PCV2d-specific interferon-γ secreting cells at 21 dpc and a significant reduction in PCV2d viremia at 14 dpc when compared with the ready-to-use bivalent-vaccinated and challenged groups. These results offer supporting evidence that vaccination during the weaning to finishing period against M. hyopneumoniae and PCV2 is efficacious for controlling diseases caused by these two pathogens.
format Online
Article
Text
id pubmed-7492382
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74923822020-09-25 A Dual Swine Challenge With Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae Used to Compare a Combination of Mixable Monovalent PCV2 and Monovalent M. hyopneumoniae Vaccines With a Ready-to Use PCV2 and M. hyopneumoniae Bivalent Vaccine Yang, Siyeon Oh, Taehwan Park, Kee Hwan Cho, Hyejean Chae, Chanhee Front Vet Sci Veterinary Science The present study evaluated the efficacy of swine vacciation using a combination of mixable monovalents for porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae against a ready-to-use bivalent vaccine under experimental conditions. Pigs at 21 days of age were administered either a combination of two mixable monovalent vaccines or a bivalent vaccine containing PCV2 and M. hyopneumoniae. Vaccination was followed with an M. hyopneumoniae challenge at 42 days of age (−14 days post challenge, dpc) and a PCV2d challenge at 56 days of age (0 dpc). Each vaccinated and challenged group was compared with the unvaccinated and challenged group for clinical, microbiological, immunologic, and pathologic differences. Clinically, two vaccinated and challenged groups showed minimal respiratory diseases that was characterized by occasionally coughing and sneezing. A significant difference was not calculated in the average daily weight gain, nasal shedding of M. hyopneumoniae, and pathological lesions between two vaccinated and challenged groups. A combination of two monovalent vaccines mixed into a combo prior to vaccination followed by challenge resulted in increased numbers of PCV2d-specific interferon-γ secreting cells at 21 dpc and a significant reduction in PCV2d viremia at 14 dpc when compared with the ready-to-use bivalent-vaccinated and challenged groups. These results offer supporting evidence that vaccination during the weaning to finishing period against M. hyopneumoniae and PCV2 is efficacious for controlling diseases caused by these two pathogens. Frontiers Media S.A. 2020-09-02 /pmc/articles/PMC7492382/ /pubmed/32984414 http://dx.doi.org/10.3389/fvets.2020.00579 Text en Copyright © 2020 Yang, Oh, Park, Cho and Chae. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Yang, Siyeon
Oh, Taehwan
Park, Kee Hwan
Cho, Hyejean
Chae, Chanhee
A Dual Swine Challenge With Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae Used to Compare a Combination of Mixable Monovalent PCV2 and Monovalent M. hyopneumoniae Vaccines With a Ready-to Use PCV2 and M. hyopneumoniae Bivalent Vaccine
title A Dual Swine Challenge With Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae Used to Compare a Combination of Mixable Monovalent PCV2 and Monovalent M. hyopneumoniae Vaccines With a Ready-to Use PCV2 and M. hyopneumoniae Bivalent Vaccine
title_full A Dual Swine Challenge With Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae Used to Compare a Combination of Mixable Monovalent PCV2 and Monovalent M. hyopneumoniae Vaccines With a Ready-to Use PCV2 and M. hyopneumoniae Bivalent Vaccine
title_fullStr A Dual Swine Challenge With Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae Used to Compare a Combination of Mixable Monovalent PCV2 and Monovalent M. hyopneumoniae Vaccines With a Ready-to Use PCV2 and M. hyopneumoniae Bivalent Vaccine
title_full_unstemmed A Dual Swine Challenge With Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae Used to Compare a Combination of Mixable Monovalent PCV2 and Monovalent M. hyopneumoniae Vaccines With a Ready-to Use PCV2 and M. hyopneumoniae Bivalent Vaccine
title_short A Dual Swine Challenge With Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae Used to Compare a Combination of Mixable Monovalent PCV2 and Monovalent M. hyopneumoniae Vaccines With a Ready-to Use PCV2 and M. hyopneumoniae Bivalent Vaccine
title_sort dual swine challenge with porcine circovirus type 2 (pcv2) and mycoplasma hyopneumoniae used to compare a combination of mixable monovalent pcv2 and monovalent m. hyopneumoniae vaccines with a ready-to use pcv2 and m. hyopneumoniae bivalent vaccine
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492382/
https://www.ncbi.nlm.nih.gov/pubmed/32984414
http://dx.doi.org/10.3389/fvets.2020.00579
work_keys_str_mv AT yangsiyeon adualswinechallengewithporcinecircovirustype2pcv2andmycoplasmahyopneumoniaeusedtocompareacombinationofmixablemonovalentpcv2andmonovalentmhyopneumoniaevaccineswithareadytousepcv2andmhyopneumoniaebivalentvaccine
AT ohtaehwan adualswinechallengewithporcinecircovirustype2pcv2andmycoplasmahyopneumoniaeusedtocompareacombinationofmixablemonovalentpcv2andmonovalentmhyopneumoniaevaccineswithareadytousepcv2andmhyopneumoniaebivalentvaccine
AT parkkeehwan adualswinechallengewithporcinecircovirustype2pcv2andmycoplasmahyopneumoniaeusedtocompareacombinationofmixablemonovalentpcv2andmonovalentmhyopneumoniaevaccineswithareadytousepcv2andmhyopneumoniaebivalentvaccine
AT chohyejean adualswinechallengewithporcinecircovirustype2pcv2andmycoplasmahyopneumoniaeusedtocompareacombinationofmixablemonovalentpcv2andmonovalentmhyopneumoniaevaccineswithareadytousepcv2andmhyopneumoniaebivalentvaccine
AT chaechanhee adualswinechallengewithporcinecircovirustype2pcv2andmycoplasmahyopneumoniaeusedtocompareacombinationofmixablemonovalentpcv2andmonovalentmhyopneumoniaevaccineswithareadytousepcv2andmhyopneumoniaebivalentvaccine
AT yangsiyeon dualswinechallengewithporcinecircovirustype2pcv2andmycoplasmahyopneumoniaeusedtocompareacombinationofmixablemonovalentpcv2andmonovalentmhyopneumoniaevaccineswithareadytousepcv2andmhyopneumoniaebivalentvaccine
AT ohtaehwan dualswinechallengewithporcinecircovirustype2pcv2andmycoplasmahyopneumoniaeusedtocompareacombinationofmixablemonovalentpcv2andmonovalentmhyopneumoniaevaccineswithareadytousepcv2andmhyopneumoniaebivalentvaccine
AT parkkeehwan dualswinechallengewithporcinecircovirustype2pcv2andmycoplasmahyopneumoniaeusedtocompareacombinationofmixablemonovalentpcv2andmonovalentmhyopneumoniaevaccineswithareadytousepcv2andmhyopneumoniaebivalentvaccine
AT chohyejean dualswinechallengewithporcinecircovirustype2pcv2andmycoplasmahyopneumoniaeusedtocompareacombinationofmixablemonovalentpcv2andmonovalentmhyopneumoniaevaccineswithareadytousepcv2andmhyopneumoniaebivalentvaccine
AT chaechanhee dualswinechallengewithporcinecircovirustype2pcv2andmycoplasmahyopneumoniaeusedtocompareacombinationofmixablemonovalentpcv2andmonovalentmhyopneumoniaevaccineswithareadytousepcv2andmhyopneumoniaebivalentvaccine